JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia
| Authors | |
|---|---|
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | CLINICAL HEMORHEOLOGY AND MICROCIRCULATION |
| MU Faculty or unit | |
| Citation | |
| Web | https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch221678 |
| Doi | http://dx.doi.org/10.3233/CH-221678 |
| Keywords | Essential thrombocythemia; thrombosis; risk factor; JAK2V617F mutation; extracellular vesicles |
| Description | The clinical course of essential thrombocythemia (ET) is complicated with thrombosis which significantly impacts patients’ mortality. Studies have identified JAK2V617F mutation as an independent risk factor for thrombosis. Circulating extracellular vesicles (EVs) were evaluated in several studies regarding myeloproliferative neoplasms and thrombosis as potential biomarkers. The present study investigates the relationship between JAK2V617F mutation and EVs levels in 119 ET patients. Our analyses revealed that JAK2V617F-positive patients are at a significantly increased risk of thrombosis within five years before the ET diagnosis (hazard ratio [95% CI]: 11.9 [1.7–83.7], P?=?0.013), and that JAK2V617F mutation is an independent risk factor for thrombosis at ET diagnosis or during the follow-up (hazard ratio [95% CI]: 3.56 [1.47–8.62], P?=?0.005). ET patients have higher levels of platelet-EVs, erythrocyte-EVs and procoagulant activity of EVs than the healthy population. Absolute and relative counts of platelet-EVs are increased in the presence of JAK2V617F mutation (P?=?0.018, P?=?0.024, respectively). In conclusion, our results support the role of JAK2V617F mutation in the pathogenesis of thrombosis in essential thrombocythemia through enhancing platelet activation. |